Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Protein C is a medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis. Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade.
- Mechanism
- Curator reviewed
Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade. Also known as blood coagulation factor XIV, Protein C is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). Once in its activated form, APC functions as a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S. APC exerts its effect by inactivating essential components of the coagulation cascade (specifically factors V and VIII), which leads to a decrease in thrombin formation, and therefore a reduction in clot formation.
- Primary indication
- Protein C concentrate is indicated for pediatric and adult patients with severe congenital protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.Curator reviewed · 4 structured indications
- First approval
- Canada, 2007 · United States, 2010 · European Union, 2016
- Also known as
- autoprothrombin IIA · blood coagulation factor XIV · Human protein C · Protein C (coagulation inhibitor) · Protein C concentrate
- Brand names
- Balfaxar
- Beriplex
- Ceprotin
- Kcentra
- Octaplex
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Protein C, and which of those have an active Phase 3 trial?